Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating that the stock is overvalued. The company has a P/E ratio of 16, a Price to Book Value of 1.03, and an EV to EBITDA ratio of 4.61. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while LifeVantage Corp. presents a more attractive valuation with a P/E of 14.81.
Given the current metrics and the valuation grade, USANA Health Sciences appears to be overvalued relative to its peers. Although specific return data is not available, the lack of favorable returns compared to the S&P 500 may reinforce the perception of overvaluation.